Profile picture

Doctor Antonio J Vallejo-Vaz

University of Seville, Seville (Spain)
Follow
Logo ESC

Contributor content

Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study
Presentation
Atherothrombotic residual risk in coronary and peripheral artery disease patients on guideline-recommended antiplatelet monotherapy: baseline preliminary results from the RESRISK study
Read more
The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries
Presentation
The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) global registry: analyses from over 55,000 cases and 68 countries
Read more
Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials
Presentation
Predictive factors for alirocumab dose increase in patients with hypercholesterolaemia and high cardiovascular risk: from the ODYSSEY COMBO I and II trials
Read more
Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial
Presentation
Primary prevention of patients with high LDL-cholesterol levels greater than 4.9 mmol/l: analysis from the WOSCOPS trial
Read more

ESC 365 is supported by

novartis Explore sponsored resources